Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study

BACKGROUND: The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hae Jin, Jeong, In Kyung, Hur, Kyu Yeon, Kim, Soo-Kyung, Noh, Jung Hyun, Chun, Sung Wan, Kang, Eun Seok, Rhee, Eun-Jung, Choi, Sung Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532178/
https://www.ncbi.nlm.nih.gov/pubmed/35295073
http://dx.doi.org/10.4093/dmj.2021.0183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532178/
https://www.ncbi.nlm.nih.gov/pubmed/35295073
http://dx.doi.org/10.4093/dmj.2021.0183

Ejemplares similares